iSpecimen Inc. (NASDAQ:ISPC - Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 8,400 shares, a decline of 86.9% from the September 30th total of 64,200 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily volume of 286,300 shares, the short-interest ratio is presently 0.0 days.
iSpecimen Price Performance
ISPC stock traded down $0.54 during mid-day trading on Friday, reaching $4.73. 41,725 shares of the company's stock were exchanged, compared to its average volume of 168,971. The company has a market cap of $61.84 million, a price-to-earnings ratio of -3.88 and a beta of 1.59. iSpecimen has a 12-month low of $3.41 and a 12-month high of $14.60. The stock's 50 day moving average is $2.91 and its 200 day moving average is $1.21.
iSpecimen (NASDAQ:ISPC - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. The firm had revenue of $2.86 million for the quarter. iSpecimen had a negative net margin of 97.03% and a negative return on equity of 115.36%.
About iSpecimen
(
Get Free Report)
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iSpecimen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iSpecimen wasn't on the list.
While iSpecimen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
